

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Walter Ling, M.D.

Role(s) in Work Group: Member, Substance-Related Disorders Work Group

Institutional Affiliation(s): UCLA

City, State: Los Angeles, CA

Biographical Sketch:

Dr. Ling is Professor of Psychiatry and Director of the Integrated Substance Abuse Programs (ISAP) at UCLA, Los Angeles, CA, USA, one of the foremost substance abuse research groups in the US and worldwide. The scope of the group’s research has included the evaluation of medications and the development of psychosocial strategies for the treatment of opiate, cocaine, methamphetamine, alcohol, and nicotine abuse and dependence

Dr. Walter Ling is a board-certified neurologist and psychiatrist, licensed to practice in the state of California. He is active in both research and clinical work, having been listed in the ‘Best Doctors of America’, ‘Best Doctors in the West’, and ‘Best Doctors in Los Angeles’. He was also named by ‘Good Housekeeping’ magazine as one of the 327 best mental health clinicians in the US.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
None		

The two tables below represent Dr. Walter Ling’s disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Walter Ling has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <ol style="list-style-type: none"> 1. Consultation Fees (include scientific advisory boards) 2. Full- or Part-time Employee 3. Industry-related Grant-Research Support received or pending 4. Honoraria (includes Speakers’ Bureau) 5. Stock or other financial options 	<ol style="list-style-type: none"> 6. Expert testimony 7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product) 8. Patents received or pending 9. Officer, director/trustee, executive (specify) 10. Other (specify)
--	---

UPDATED 4.29.08

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Hythiam	2005--2007	1,3,4
Reckitt Benckiser	2005--2007	3,4
Titan Pharmaceuticals	2005-2007	1,3,4
US World Meds	2005-2007	1

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
Reckitt Benckiser	2008	3,4
Titan Pharmaceuticals	2008	1,3,4
Hythiam	2008	3
US World Meds	2008	1